Clinical Trials Logo

Dyskinesia, Drug-Induced clinical trials

View clinical trials related to Dyskinesia, Drug-Induced.

Filter by:

NCT ID: NCT05297201 Recruiting - Parkinson Disease Clinical Trials

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

NCT ID: NCT05148884 Completed - Clinical trials for Medication-Induced Dyskinesia

Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.

NCT ID: NCT05116813 Recruiting - Parkinson Disease Clinical Trials

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Start date: October 25, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

NCT ID: NCT04857359 Recruiting - Parkinson Disease Clinical Trials

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Start date: August 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

NCT ID: NCT04147949 Not yet recruiting - Parkinson Disease Clinical Trials

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Start date: August 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia. The trial will be conducted in two treatment periods, in which each treatment period will consist of 14 days. The two treatment periods will be separated by a 1-week washout period. During the first treatment period, subjects meeting all eligibility criteria will be randomly assigned to receive either 1440 mg AV-101 or placebo in a 1:1 ratio. AV-101 or placebo will be administered BID for 14 days (every 12 hours). After the washout period, all subjects will be crossed over to receive the alternate treatment during the second treatment period (14-day period). On the last day of each treatment period (Visit 4 [Day 14] and Visit 7 [Day35]), subjects will be assessed in clinic while in the practically "off" state and will receive the morning dose of the study drug at the clinic. This will be followed, within 25-30 minutes, by oral administration of a dose of levodopa that is 150% of the subject's normal dose. Assessments of dyskinesia and PD motor symptoms will be performed before and after levodopa/carbidopa administration.

NCT ID: NCT04064294 Recruiting - Parkinson Disease Clinical Trials

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

STAT-PD
Start date: June 1, 2019
Phase:
Study type: Observational

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

NCT ID: NCT03987750 Withdrawn - Parkinson Disease Clinical Trials

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Start date: October 2019
Phase: Phase 3
Study type: Interventional

This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced dyskinesia. Eligible participants will be randomized to one of three treatment groups to receive adjunctive daily treatment with either safinamide 100 mg, safinamide 150 mg or placebo in a 1:1:1 ratio. Outcome will be assessed after 26 weeks of treatment.

NCT ID: NCT03354455 Completed - Parkinson Disease Clinical Trials

Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Using a within‐subject cross‐over design, we will include 20 patients with Parkinson disease (PD) and peak‐of‐dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic medication. On two separate days, each patient will receive off‐line, effective (high‐intensity) or ineffective (low‐intensity) 1 Hz repetitive transcranial magnetic stimulation (rTMS) of the presupplementary motor area (preSMA) before functional magnetic resonance (fMRI). Immediately after the patient will perform a Go/No-Go task during fMRI in the the OFF state for 9 minutes. Then the scan is paused and the patient will receive 200 mg fast‐acting oral levodopa and undergo whole‐brain task‐related fMRI at 3 Tesla until peak‐of‐dose dyskinesia will emerge. During task‐related fMRI, patients has to click on a mouse with their right hand (Right‐Go), left hand (Left‐Go), or no action (No‐Go) in response to arbitrary visual cues. The patients will also be tested for different aspects of impulsivity using neuropsychological questionnaires and computerized tests.

NCT ID: NCT02657681 Completed - Parkinson's Disease Clinical Trials

Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a randomized sham-controlled double-blind study to test the hypothesis that transcranial static magnetic field stimulation (tSMS) of the motor cortex improves levodopa-induced dyskinesias in patients with Parkinson's disease. Half of the patients will receive real tSMS treatment, the other half will receive sham treatment (placebo).

NCT ID: NCT01789047 Terminated - Clinical trials for Idiopathic Parkinson's Disease

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

TOP-DYSK
Start date: March 2013
Phase: Phase 2
Study type: Interventional

The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD) patients who continue to have dyskinesia on amantadine.